Aliases & Classifications for Impotence

MalaCards integrated aliases for Impotence:

Name: Impotence 12 54 15
Erectile Dysfunction 12 54 42 15 17 70
Erectile Dysfunction Adverse Event 70
Sexual Impotence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1875
UMLS 70 C0242350 C1961100

Summaries for Impotence

MedlinePlus : 42 Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and priapism, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Impotence is PRL (Prolactin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs Nebivolol and Selegiline have been mentioned in the context of this disorder. Affiliated tissues include prostate, endothelial and smooth muscle, and related phenotypes are nervous system and normal

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 615)
# Related Disease Score Top Affiliating Genes
1 vasculogenic impotence 32.8 PDE5A ALDH7A1
2 priapism 31.3 PDE5A NOS3 NOS2 ARG2
3 low compliance bladder 31.1 PDE5A KCNMA1
4 hyperprolactinemia 31.1 VIP SHBG PRL
5 nonarteritic anterior ischemic optic neuropathy 31.1 PDE5A NOS3 EDN1
6 lipoprotein quantitative trait locus 31.1 PDE5A NOS3 NOS2 KNG1 EDN1
7 nasopharyngitis 31.0 SEPTIN3 PDE5A CYP3A4
8 angina pectoris 30.9 NOS3 KNG1 EDN1
9 type 2 diabetes mellitus 30.9 SHBG PRL PDE5A NOS3 NOS2 NOS1
10 ischemia 30.8 PDE5A NOS3 NOS2 NOS1 KNG1 EDN1
11 vascular disease 30.7 NOS3 NOS2 NOS1 KNG1 EDN1
12 diabetes mellitus 30.7 SHBG PRL PDE5A NOS3 NOS2 NOS1
13 congestive heart failure 30.7 PDE5A NOS3 KNG1 EDNRA EDN1
14 heart disease 30.7 PRL PDE5A NOS3 NOS2 KNG1 EDNRA
15 myocardial infarction 30.7 SHBG PDE5A NOS3 NOS1 KNG1 EDN1
16 arteriosclerosis 30.6 SHBG NOS3 EDNRA EDN1
17 prostatitis 30.6 PRL PDE5A KLK3
18 peyronie disease 30.6 PDE5A NOS2
19 orthostatic intolerance 30.6 NOS3 NOS2 EDN1
20 hypoactive sexual desire disorder 30.6 SHBG PDE5A
21 alopecia, androgenetic, 1 30.5 SRD5A1 SHBG
22 body mass index quantitative trait locus 11 30.5 SHBG PDE5A NOS3 NOS1 KNG1 EDNRA
23 pulmonary hypertension 30.5 VIP PDE5A NOS3 NOS2 EDNRA EDN1
24 urethral stricture 30.5 PDE5A KLK3
25 androgenic alopecia 30.4 SRD5A1 SHBG PRL KLK3
26 gynecomastia 30.4 SRD5A1 SHBG PRL KLK3 CYP3A4
27 varicocele 30.4 SHBG PRL NOS3 NOS2
28 diabetic polyneuropathy 30.4 NOS3 NOS2 NOS1
29 portal hypertension 30.3 NOS3 EDNRA EDN1
30 diabetic angiopathy 30.3 NOS3 NOS2 EDN1
31 osteoporosis 30.2 SHBG PRL NOS3 EDN1 CYP3A4 ALDH7A1
32 prostatic hyperplasia, benign 30.2 SRD5A1 PDE5A KLK3
33 pheochromocytoma 30.2 VIP PRL KNG1 EDNRA EDN1
34 cardiovascular system disease 30.2 SHBG PDE5A NOS3 NOS2 KNG1 EDNRA
35 psychosexual disorder 30.2 SHBG PRL PDE5A ALDH7A1
36 migraine with or without aura 1 30.2 VIP PRL PDE5A NOS3 NOS1 KNG1
37 constipation 30.1 VIP NOS2 NOS1 CYP3A4
38 stuttering 30.1 VIP SHBG PDE5A
39 hyperandrogenism 30.1 SRD5A1 SHBG PRL
40 prostatic adenoma 30.1 SRD5A1 SHBG PRL KLK3
41 acne 30.1 SRD5A1 SHBG PRL
42 alopecia 30.0 SRD5A1 SHBG PRL EDNRA
43 sexual disorder 29.9 SHBG SEPTIN8 SEPTIN6 SEPTIN3 PRL PDE5A
44 asthma 29.9 VIP NOS2 NOS1 KNG1 KLK3 EDN1
45 hypertension, essential 29.6 VIP SHBG PRL PDE5A PDE3A NOS3
46 disease of mental health 28.5 VIP SHBG SEPTIN8 SEPTIN6 SEPTIN3 PRL
47 multiple system atrophy 1 11.1
48 autonomic nervous system disease 11.1
49 paroxysmal nocturnal hemoglobinuria 1 11.0
50 tabes dorsalis 11.0

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:


tremor; angina pectoris; equilibration disorder; pelvic pain; symptom/complaint potency (excluding p07 p08); inability to maintain erection; unable to perform sex

MGI Mouse Phenotypes related to Impotence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.7 ALDH7A1 EDN1 EDNRA KCNMA1 NOS1 NOS2
2 normal MP:0002873 9.36 ALDH7A1 EDN1 EDNRA KLK3 NOS1 NOS3

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
2
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
7
Nitric Oxide Approved Phase 4 10102-43-9 145068
8
Allantoin Approved Phase 4 97-59-6 204
9
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
14
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
15
Testosterone Approved, Investigational Phase 4 58-22-0 6013
16
Methyltestosterone Approved Phase 4 58-18-4 6010
17
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
18
Testosterone enanthate Approved Phase 4 315-37-7 9416
19
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
20
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
21 Liver Extracts Phase 4
22 Protective Agents Phase 4
23 Neuroprotective Agents Phase 4
24 Monoamine Oxidase Inhibitors Phase 4
25 Antiparkinson Agents Phase 4
26 Citrate Phase 4
27 Phosphodiesterase 5 Inhibitors Phase 4
28 Sildenafil Citrate Phase 4 171599-83-0
29 Immunosuppressive Agents Phase 4
30 Immunologic Factors Phase 4
31 insulin Phase 4
32 Insulin, Globin Zinc Phase 4
33 Angiotensin Receptor Antagonists Phase 4
34 Antihypertensive Agents Phase 4
35 Chelating Agents Phase 4
36 Calcium, Dietary Phase 4
37 Adrenergic alpha-Antagonists Phase 4
38 Adrenergic Antagonists Phase 4
39 Mydriatics Phase 4
40 Yohimbe Phase 4
41 Calcineurin Inhibitors Phase 4
42 Giapreza Phase 4
43 Angiotensinogen Phase 4
44 Angiotensin II Type 1 Receptor Blockers Phase 4
45 Anesthetics, Local Phase 4
46 Vardenafil Dihydrochloride Phase 4
47 Androgens Phase 4
48 Hormones Phase 4
49 Hormone Antagonists Phase 4
50 Testosterone 17 beta-cypionate Phase 4

Interventional clinical trials:

(show top 50) (show all 481)
# Name Status NCT ID Phase Drugs
1 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
2 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
3 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
4 Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction Unknown status NCT02943356 Phase 4 Tadalafil
5 Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction. Unknown status NCT01885988 Phase 4 Nebivolol;Sugar Pill
6 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
7 The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction Unknown status NCT00313898 Phase 4 sildenafil (viagra)
8 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
9 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
10 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4 Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
11 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
12 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
13 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy Completed NCT00422578 Phase 4 tadalafil
14 An Evaluation of Semen Characteristics After 40 Weeks Daily Dosing With 20 mg Tadalafil Completed NCT00382135 Phase 4 tadalafil;placebo
15 Correlation of Flow Mediated Dilation of Brachial Artery and Carotid Intima Media Thickness With Erectile Dysfunction Severity and Clinical Response to PDE 5 Inhibitor in Hypertensive Men Completed NCT01084187 Phase 4 Vardenafil
16 Evaluation of the Clinical and Molecular Efficacy of Daily Avanafil in Egyptian Males With Erectile and Endothelial Dysfunction (Randomized Placebo-Controlled Study) Completed NCT04374994 Phase 4 Avanafil 50 MG;Placebo oral tablet
17 A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
18 Evaluation of Systemic and Penile Microvascular Endothelial Function and Arterial Pressure After Chronic Administration of Sildenafil in Hypertensive Men With Erectile Dysfunction Completed NCT02620995 Phase 4 sildenafil citrate
19 Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction Completed NCT00512707 Phase 4 Sildenafil citrate (open label);Testosterone gel
20 A Multi-Center, Parallel Group, Flexible Dose Trial With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Assess The Impact Of Viagra On The Sexual Satisfaction Of Men With Mild Erectile Dysfunction Completed NCT00301262 Phase 4 Viagra (Sildenafil citrate)
21 A Multi-Center, Double-Blind Placebo Controlled, Flexible-Dose Study With An Open-Label Phase To Assess The Efficacy Of Sildenafil Citrate On Erectile Function And Intercourse Satisfaction As Well As To Validate The Sexual Experience Questionnaire And Its Treatment Responsiveness In Men With Erectile Dysfunction Completed NCT00147628 Phase 4 sildenafil citrate;placebo for sildenafil citrate
22 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study To Assess The Efficacy And Safety Of Viagra (Sildenafil Citrate) In Men With Erectile Dysfunction (ED) Who Do Not Self Identify. Completed NCT00343200 Phase 4 Placebo;Viagra (sildenafil citrate)
23 Open Label, Multicenter, Non Comparative Study, To Confirm The Efficacy And Tolerability Of Viagra In Subjects With Erectile Dysfunction And Arterial Hypertension Who Are Taking Antihypertensive Treatment. Completed NCT00150358 Phase 4 Sildenafil Citrate
24 An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) Completed NCT00245596 Phase 4 sildenafil
25 A Multicenter, Double-Blind Placebo Controlled, Fixed Dose Study With An Open-Label, Flexible Dose Phase To Assess The Efficacy Of Sildenafil Citrate In Providing A Better Sexual Experience Including Quality Of Erections And Satisfaction In Men With Erectile Dysfunction Completed NCT00245258 Phase 4 Sildenafil Citrate
26 A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction Completed NCT00249730 Phase 4 Sildenafil
27 The Use and Efficacy of Sildenafil in Diabetic Men With Erectile Dysfunction: the Impact on Endothelial Function, a Pilot Feasibility Study Completed NCT00199563 Phase 4 Viagra
28 An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) Completed NCT00151463 Phase 4 sildenafil citrate
29 A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
30 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose Completed NCT00137072 Phase 4 Viagra (Sildenafil Citrate) 100 mg
31 Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil Completed NCT00159848 Phase 4
32 A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED) Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
33 Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II Completed NCT00143260 Phase 4 Viagra (Sildenafil Citrate) 100 mg
34 Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference Completed NCT00547352 Phase 4 tadalafil;sildenafil
35 Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction? Completed NCT00547599 Phase 4 tadalafil
36 A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction Completed NCT00547092 Phase 4 tadalafil;sildenafil
37 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia Completed NCT00379756 Phase 4 LEVITRA (vardenafil);placebo
38 Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors Completed NCT01122264 Phase 4 Tadalafil;Sildenafil Citrate
39 A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy Completed NCT00106392 Phase 4 Tacrolimus;Placebo
40 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction Completed NCT01768676 Phase 4 avanafil;Placebo
41 Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function Completed NCT01130532 Phase 4 Tadalafil;Placebo
42 A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Effects of 5 mg Tadalafil (IC351, LY450190) and 50 mg Sildenafil Administered Once Daily for 6 Months on Visual Function in Healthy Subjects or Subjects With Mild Erectile Dysfunction Completed NCT00333281 Phase 4 tadalafil
43 Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patient With Type II Diabetes. Multicentric Study. Completed NCT01180283 Phase 4 lodenafil carbonate
44 Satisfaction With the Treatment, Confidence and Naturalness in Engaging in Sexual Activity in Men With Psychogenic Erectile Dysfunction: Randomized Controlled Trial of Three Therapeutic Approaches. Completed NCT01153204 Phase 4 Sildenafil citrate
45 A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico. Completed NCT00468650 Phase 4 sildenafil citrate
46 A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate Completed NCT00159900 Phase 4 Sildenafil Citrate
47 Characterisation of Relative Bioavailability and Assessment of Bioequivalence of Two Generic Yohimbine Formulations in Comparison With a Marketed Reference Product - an Open, Randomised, Single Dose, 3-period Change-over Study Completed NCT00975325 Phase 4 Yohimbine;Yohimbine
48 Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals Completed NCT00662441 Phase 4 Levitra (Vardenafil, BAY38-9456)
49 A Randomized, Double-blind, Crossover Study to Evaluate the Duration of Erection Following Vardenafil (10mg) Administration for Four Weeks in a Fixed Dose Regimen Compared to Placebo in Males With ED Completed NCT00663728 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
50 REALISE Levitra® - Real Life Safety and Efficacy of Levitra Completed NCT00663598 Phase 4 Levitra (Vardenafil, BAY38-9456)

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ginseng Preparation
Methyltestosterone
METHYLTESTOSTERONE PWDR
Papaverine
Papaverine Hydrochloride
yohimbine
Yohimbine hydrochloride

Genetic Tests for Impotence

Anatomical Context for Impotence

MalaCards organs/tissues related to Impotence:

40
Prostate, Endothelial, Smooth Muscle, Spinal Cord, Heart, Bone, Kidney

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 21018)
# Title Authors PMID Year
1
The effect of COVID-19 epidemic on the sexual function of healthcare professionals. 42 61
33438223 2021
2
Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis. 42 61
33663041 2021
3
Hyperhomocysteinemia: Focus on Endothelial Damage as a Cause of Erectile Dysfunction. 42 61
33401548 2021
4
Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release. 61 54
20043970 2010
5
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. 61 54
20402554 2010
6
T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. 54 61
19800665 2010
7
Adaptive spaced education improves learning efficiency: a randomized controlled trial. 61 54
20022032 2010
8
Pharmacotherapy for erectile dysfunction. 61 54
20092451 2010
9
Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. 61 54
19907424 2010
10
Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. 61 54
19686427 2009
11
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. 61 54
19884625 2009
12
[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]. 61 54
20112748 2009
13
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. 61 54
19701217 2009
14
Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor? 61 54
19234311 2009
15
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 61 54
19377497 2009
16
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 61 54
19387454 2009
17
Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. 61 54
19466514 2009
18
Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. 54 61
19210710 2009
19
EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. 61 54
19036180 2009
20
In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being. 61 54
19143914 2009
21
[Psychosis and sexuality]. 54 61
19365914 2009
22
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. 61 54
19138360 2009
23
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. 61 54
19010346 2009
24
Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. 61 54
19125990 2009
25
[Tadalafil for erectile dysfunction: excellent safety and tolerance]. 54 61
19288756 2009
26
Online spaced education to teach urology to medical students: a multi-institutional randomized trial. 61 54
18614145 2009
27
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. 61 54
19170852 2009
28
PDE5 inhibitors in non-urological conditions. 61 54
19860698 2009
29
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. 61 54
18976905 2008
30
5-alpha reductase inhibitors and erectile dysfunction: the connection. 54 61
19090946 2008
31
The role of combination medical therapy in benign prostatic hyperplasia. 61 54
19002123 2008
32
New treatments for localized prostate cancer. 61 54
19095127 2008
33
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. 61 54
18528398 2008
34
Pulmonary embolism after tadalafil ingestion. 54 61
18548330 2008
35
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. 54 61
18331258 2008
36
[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. 61 54
18998474 2008
37
The effect of 5 alpha-reductase inhibitors on erectile function. 61 54
18421068 2008
38
Potent inhibition of human phosphodiesterase-5 by icariin derivatives. 54 61
18778098 2008
39
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. 61 54
18674473 2008
40
Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. 54 61
18644193 2008
41
Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. 61 54
18395326 2008
42
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. 54 61
18423715 2008
43
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 61 54
18281145 2008
44
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]. 61 54
18572866 2008
45
[Expressions of eNOS and connexin 43 in the penile tissue of rats with diabetic erectile dysfunction]. 61 54
18572862 2008
46
Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. 54 61
18385912 2008
47
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. 61 54
18075506 2008
48
The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. 61 54
18304285 2008
49
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. 61 54
18086159 2008
50
Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. 61 54
18082643 2008

Variations for Impotence

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 PDE5A PDE3A NOS3 NOS2 NOS1 KNG1
2 12.71 NOS2 KNG1 KLK3 EDNRA EDN1
3
Show member pathways
12.38 PDE5A PDE3A NOS3 KNG1 KCNMA1 EDNRA
4
Show member pathways
12.35 NOS3 KCNMA1 EDNRA EDN1
5 12.26 NOS3 NOS2 NOS1 EDNRA
6 12.19 VIP PDE3A EDNRA EDN1
7
Show member pathways
12.01 PDE5A PDE3A NOS3 NOS2 NOS1 KCNMA1
8 11.81 NOS3 NOS2 EDN1
9 11.63 SEPTIN8 SEPTIN6 SEPTIN3
10 11.57 PDE3A KCNMA1 EDNRA EDN1
11
Show member pathways
11.48 NOS3 NOS2 NOS1
12
Show member pathways
11.32 NOS3 NOS2 NOS1 ARG2 ALDH7A1
13
Show member pathways
11.3 NOS3 NOS2 NOS1
14 11.22 NOS3 EDNRA EDN1
15 11.15 PRL EDNRA EDN1
16 11.1 NOS3 NOS2 NOS1
17
Show member pathways
11.05 NOS3 NOS2 NOS1 ARG2
18 11.01 NOS3 NOS2 NOS1
19
Show member pathways
10.72 PDE5A PDE3A NOS3 NOS2 NOS1 KCNMA1
20 10.45 NOS3 NOS2 NOS1
21 10.37 PDE5A NOS3 NOS2 NOS1

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vesicle membrane GO:0012506 9.43 NOS3 NOS2 NOS1
2 cell division site GO:0032153 9.33 SEPTIN8 SEPTIN6 SEPTIN3
3 septin complex GO:0031105 9.13 SEPTIN8 SEPTIN6 SEPTIN3
4 septin ring GO:0005940 8.8 SEPTIN8 SEPTIN6 SEPTIN3

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 10.02 SRD5A1 NOS3 NOS2 NOS1 CYP3A4 ALDH7A1
2 response to lipopolysaccharide GO:0032496 9.78 NOS3 NOS2 NOS1 EDN1
3 cellular protein localization GO:0034613 9.77 SEPTIN8 SEPTIN6 SEPTIN3
4 regulation of blood pressure GO:0008217 9.75 NOS3 EDNRA EDN1
5 cell redox homeostasis GO:0045454 9.7 NOS3 NOS2 NOS1
6 response to hormone GO:0009725 9.69 NOS3 NOS2 NOS1
7 response to hypoxia GO:0001666 9.65 NOS2 NOS1 KCNMA1 EDNRA EDN1
8 vasoconstriction GO:0042310 9.62 EDNRA EDN1
9 androgen metabolic process GO:0008209 9.62 SRD5A1 CYP3A4
10 striated muscle contraction GO:0006941 9.61 NOS1 ARG2
11 negative regulation of blood coagulation GO:0030195 9.61 KNG1 EDN1
12 negative regulation of blood pressure GO:0045776 9.61 NOS3 NOS2 NOS1
13 artery smooth muscle contraction GO:0014824 9.6 EDNRA EDN1
14 negative regulation of potassium ion transport GO:0043267 9.58 VIP NOS1
15 vasodilation GO:0042311 9.58 NOS3 NOS1 KNG1
16 regulation of glucose transmembrane transport GO:0010827 9.57 EDNRA EDN1
17 body fluid secretion GO:0007589 9.56 VIP EDN1
18 endothelin receptor signaling pathway GO:0086100 9.54 EDNRA EDN1
19 cytoskeleton-dependent cytokinesis GO:0061640 9.54 SEPTIN8 SEPTIN6 SEPTIN3
20 nitric oxide mediated signal transduction GO:0007263 9.5 NOS3 NOS2 NOS1
21 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.49 NOS3 EDN1
22 peptidyl-cysteine S-nitrosylation GO:0018119 9.46 NOS2 NOS1
23 positive regulation of guanylate cyclase activity GO:0031284 9.33 NOS3 NOS2 NOS1
24 arginine catabolic process GO:0006527 9.13 NOS3 NOS2 NOS1
25 nitric oxide biosynthetic process GO:0006809 8.92 NOS3 NOS2 NOS1 ARG2

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.5 VIP SHBG SEPTIN8 SEPTIN6 SEPTIN3 PRL
2 oxidoreductase activity GO:0016491 9.93 SRD5A1 NOS3 NOS2 NOS1 CYP3A4 ALDH7A1
3 heme binding GO:0020037 9.73 NOS3 NOS2 NOS1 CYP3A4
4 hormone activity GO:0005179 9.71 VIP PRL EDN1
5 molecular adaptor activity GO:0060090 9.69 SEPTIN8 SEPTIN6 SEPTIN3
6 flavin adenine dinucleotide binding GO:0050660 9.67 NOS3 NOS2 NOS1
7 NADP binding GO:0050661 9.58 NOS3 NOS2 NOS1
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0016709 9.54 NOS3 NOS2 NOS1
9 FMN binding GO:0010181 9.5 NOS3 NOS2 NOS1
10 cadmium ion binding GO:0046870 9.48 NOS3 NOS1
11 arginine binding GO:0034618 9.43 NOS3 NOS2 NOS1
12 NADPH-hemoprotein reductase activity GO:0003958 9.33 NOS3 NOS2 NOS1
13 tetrahydrobiopterin binding GO:0034617 9.13 NOS3 NOS2 NOS1
14 nitric-oxide synthase activity GO:0004517 8.8 NOS3 NOS2 NOS1

Sources for Impotence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....